Rockefeller Capital Management
AUPH icon

Rockefeller Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Rockefeller Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Hold
81,404
– – ﹤0.01% 1547
2026
Q1 		$1.21M Buy
81,404
+1,790
+2% +$26.2K ﹤0.01% 1529
2025
Q4 		$1.27M Sell
79,614
-29,551
-27% -$419K ﹤0.01% 1455
2025
Q3 		$1.21M Buy
109,165
+25,000
+30% +$273K ﹤0.01% 1340
2025
Q2 		$713K Buy
84,165
+5,000
+6% +$40.1K ﹤0.01% 1443
2025
Q1 		$636K Sell
79,165
-35
-0% -$284 ﹤0.01% 1407
2024
Q4 		$711K Buy
79,200
+35
+0% +$286 ﹤0.01% 1365
2024
Q3 		$580K Sell
79,165
-159
-0.2% -$986 ﹤0.01% 1390
2024
Q2 		$453K Buy
79,324
+159
+0.2% +$837 ﹤0.01% 1469
2024
Q1 		$397K Sell
79,165
-2,005
-2% -$13.6K ﹤0.01% 1531
2023
Q4 		$730K Buy
81,170
+5
+0% +$41 ﹤0.01% 1247
2023
Q3 		$631K Hold
81,165
– – ﹤0.01% 1237
2023
Q2 		$786K Hold
81,165
– – ﹤0.01% 1176
2023
Q1 		$889K Buy
81,165
+2,000
+3% +$17.6K ﹤0.01% 1123
2022
Q4 		$341K Hold
79,165
– – ﹤0.01% 1423
2022
Q3 		$595K Hold
79,165
– – ﹤0.01% 1204
2022
Q2 		$795K Hold
79,165
– – ﹤0.01% 1073
2022
Q1 		$980K Hold
79,165
– – ﹤0.01% 1061
2021
Q4 		$1.81M Sell
79,165
-14,420
-15% -$342K 0.01% 833
2021
Q3 		$2.07M Buy
93,585
+500
+0.5% +$7.93K 0.01% 736
2021
Q2 		$1.21M Hold
93,085
– – 0.01% 864
2021
Q1 		$1.21M Hold
93,085
– – 0.01% 726
2020
Q4 		$1.29M Sell
93,085
-1,000
-1% -$14.6K 0.01% 631
2020
Q3 		$1.39M Hold
94,085
– – 0.01% 517
2020
Q2 		$1.53M Buy
94,085
+1,000
+1% +$16K 0.02% 453
2020
Q1 		$1.35M Hold
93,085
– – 0.02% 409
2019
Q4 		$1.89M Hold
93,085
– – 0.02% 357
2019
Q3 		$497K Buy
93,085
+1,500
+2% +$9.08K 0.01% 492
2019
Q2 		$603K Hold
91,585
– – 0.01% 416
2019
Q1 		$595K Hold
91,585
– – 0.01% 456
2018
Q4 		$625K Buy
+91,585
New +$528K 0.01% 294

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's AUPH Position: Q2 2026 in Review

Rockefeller Capital Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 81,404 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1547.

Rockefeller Capital Management first reported a position in AUPH in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.07M in Q3 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Rockefeller Capital Management held 81,404 shares of Aurinia Pharmaceuticals worth $1.38M as of Q2 2026.
  • Rockefeller Capital Management left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1547 holding.
  • Rockefeller Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Rockefeller Capital Management's Aurinia Pharmaceuticals position peaked at $2.07M in Q3 2021.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.